Key Points
- Adam Crystal sold 27,000 shares on April 1 at an average price of $21.20 for $572,400, leaving him with 112,622 shares (a 19.34% reduction); the transaction was executed under a pre-arranged Rule 10b5-1 plan and disclosed in an SEC filing.
- Including four prior sales since Feb. 3, Crystal has sold a total of 132,048 shares between February and April, generating roughly $2.04 million in proceeds.
- Tango’s stock is trading near its 12‑month high ($22.20) and above the 50‑day ($14.94) and 200‑day ($11.05) moving averages, with a MarketBeat consensus of Moderate Buy and an average target of $20.67.
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) insider Adam Crystal sold 27,000 shares of the business's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $21.20, for a total value of $572,400.00. Following the sale, the insider owned 112,622 shares in the company, valued at approximately $2,387,586.40. The trade was a 19.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Adam Crystal also recently made the following trade(s):
- On Wednesday, March 25th, Adam Crystal sold 12,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $20.11, for a total transaction of $241,320.00.
- On Thursday, March 5th, Adam Crystal sold 20,251 shares of Tango Therapeutics stock. The stock was sold at an average price of $15.00, for a total transaction of $303,765.00.
- On Wednesday, February 25th, Adam Crystal sold 54,345 shares of Tango Therapeutics stock. The shares were sold at an average price of $12.77, for a total transaction of $693,985.65.
- On Tuesday, February 3rd, Adam Crystal sold 18,452 shares of Tango Therapeutics stock. The stock was sold at an average price of $12.26, for a total transaction of $226,221.52.
Tango Therapeutics Stock Performance
NASDAQ TNGX opened at $21.63 on Friday. The firm's 50 day moving average price is $14.94 and its two-hundred day moving average price is $11.05. Tango Therapeutics, Inc. has a twelve month low of $1.03 and a twelve month high of $22.20. The stock has a market cap of $3.09 billion, a price-to-earnings ratio of -24.86 and a beta of 1.31.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its earnings results on Thursday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.02. Tango Therapeutics had a negative return on equity of 50.30% and a negative net margin of 151.15%. On average, research analysts forecast that Tango Therapeutics, Inc. will post -1.19 EPS for the current fiscal year.
Analyst Ratings Changes
A number of equities research analysts have commented on the company. Weiss Ratings restated a "sell (e+)" rating on shares of Tango Therapeutics in a research report on Wednesday, January 21st. Guggenheim increased their price target on shares of Tango Therapeutics from $18.00 to $20.00 and gave the stock a "buy" rating in a research report on Friday, March 6th. Piper Sandler raised their price target on shares of Tango Therapeutics from $11.00 to $14.00 and gave the stock an "overweight" rating in a report on Friday, January 16th. Jefferies Financial Group reiterated a "buy" rating and issued a $18.00 price objective on shares of Tango Therapeutics in a research note on Thursday, March 5th. Finally, HC Wainwright increased their target price on shares of Tango Therapeutics from $13.00 to $27.00 and gave the stock a "buy" rating in a research report on Friday, March 6th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Tango Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $20.67.
View Our Latest Report on TNGX
Institutional Investors Weigh In On Tango Therapeutics
A number of large investors have recently bought and sold shares of TNGX. Seven Fleet Capital Management LP acquired a new position in Tango Therapeutics during the fourth quarter worth $1,906,000. XTX Topco Ltd acquired a new stake in shares of Tango Therapeutics in the fourth quarter worth about $335,000. VARCOV Co. acquired a new stake in shares of Tango Therapeutics in the fourth quarter worth about $261,000. Virtus Investment Advisers LLC boosted its stake in shares of Tango Therapeutics by 26.3% during the 4th quarter. Virtus Investment Advisers LLC now owns 28,452 shares of the company's stock worth $252,000 after acquiring an additional 5,920 shares in the last quarter. Finally, Tudor Investment Corp ET AL increased its holdings in shares of Tango Therapeutics by 27.4% during the 4th quarter. Tudor Investment Corp ET AL now owns 68,251 shares of the company's stock valued at $605,000 after acquiring an additional 14,679 shares during the last quarter. 78.99% of the stock is currently owned by institutional investors.
About Tango Therapeutics
(
Get Free Report)
Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.
The company's lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
